In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Soligenix, Inc. (NASDAQ:SNGX) reported that Kirk Randal J has picked up 277,631 of common stock as of 2017-06-16.
The acquisition brings the aggregate amount owned by Kirk Randal J to a total of 277,631 representing a 4.9% stake in the company.
For those not familiar with the company, Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.
A glance at Soligenix, Inc. (NASDAQ:SNGX)’s key stats reveals a current market capitalization of $13.19 Million based on $3.80 Million shares outstanding and a price at last close of $2.02 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-16, Schaber picked up 15,804 at a purchase price of $3.16. This brings their total holding to 25,095 as of the date of the filing.
On the sell side, the most recent transaction saw Kirk unload 1,881 shares at a sale price of $2.54. This brings their total holding to 85,397.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Soligenix, Inc. (NASDAQ:SNGX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.